continue

Equity | India | Building Materials 19 January 2007



Reena Verma Bhasin, CFA >> +91 22 6632 8667 Research Analyst DSP Merrill Lynch (India)

reena verma@ml.com

# Strong 3Q FY07 results, in-line with expectations

In-line results, growth to

UltraTech reported 3Q FY07 profit at Rs2.1bn, up 790% YoY and 67% QoQ. Results were in-line with our expectations. Profit growth was led by a combination of strong price realizations (+36% YoY, +3% QoQ), higher volumes (+18% YoY, +22% QoQ), and lower costs (-4%) on a QoQ basis. Our conversation with the company indicates that in addition to higher domestic cement prices, export realizations were also strong, both YoY and QoQ. Overall EBITDA/ton for the quarter was ~Rs846, up 23% QoQ.

#### Strong FY08E earnings outlook, still early to exit

We forecast UltraTech's FY08E earnings to grow 28% YoY and believe it is still early to exit the stock. Overall, we expect the Indian cement industry to ride at least two strong seasons (Jan-Jun) of demand before supply starts to balloon. We see room for upside surprise in cement prices given forecast tight capacity utilization for the industry at ~90% over the next 12-18 months.

#### Maintain Buy, PO at Rs1350/sh

Our price target of Rs1350/sh puts UltraTech at an EV/EBITDA of ~10-11x FY08E. This is based on a 20-25% discount versus valuations during the previous cyclical peak for cement in FY94-96. We think the discount captures risk of valuation compression as we move towards an expected cyclical reversal in FY09E.

#### Capex program on track

Alongwith 3Q results, UltraTech re-iterated that its capex program is on track, especially with regard to targeted commissioning of its 4mn tpa capacity expansion in 2008. We estimate UltraTech's total capex over FY07-09E at ~Rs29bn.

#### Estimates (Mar)

| (Rs)                       | 2005A | 2006A  | 2007E   | 2008E   | 2009E  |
|----------------------------|-------|--------|---------|---------|--------|
| Net Income (Adjusted - mn) | 380   | 2,016  | 7,641   | 9,762   | 6,379  |
| EPS                        | 3.06  | 16.20  | 61.38   | 78.42   | 51.24  |
| EPS Change (YoY)           | -2.1% | 429.8% | 279.0%  | 27.8%   | -34.7% |
| Dividend / Share           | 0.750 | 3.24   | 12.28   | 15.70   | 10.25  |
| Free Cash Flow / Share     | 2.37  | 6.62   | (14.23) | (27.12) | 44.95  |

#### Valuation (Mar)

|                       | 2005A   | 2006A  | 2007E  | 2008E  | 2009E  |
|-----------------------|---------|--------|--------|--------|--------|
| P/E                   | 375.06x | 70.79x | 18.68x | 14.62x | 22.38x |
| Dividend Yield        | 0.065%  | 0.283% | 1.07%  | 1.37%  | 0.894% |
| EV / EBITDA*          | 45.06x  | 28.05x | 11.50x | 9.26x  | 11.16x |
| Free Cash Flow Yield* | 0.207%  | 0.578% | -1.24% | -2.37% | 3.92%  |

<sup>\*</sup> For full definitions of iQmethod SM measures, see page 5

#### Stock Data

| Price                       | Rs1,147            |
|-----------------------------|--------------------|
| Price Objective             | Rs1,350            |
| Date Established            | 8-Jan-2007         |
| Investment Opinion          | C-1-7              |
| Volatility Risk             | HIGH               |
| 52-Week Range               | Rs492.25-Rs1,205   |
| Mrkt Val / Shares Out (mn)  | US\$3,218 / 124.4  |
| Average Daily Volume        | 33,567             |
| ML Symbol / Exchange        | XDJNF / BSE        |
| Bloomberg / Reuters         | UTCEM IN / ULTC.BO |
| ROE (2007E)                 | 49.4%              |
| Net Dbt to Eqty (Mar-2006A) | 112.6%             |
| Est. 5-Yr EPS / DPS Growth  | 10.0% / 15.0%      |
| Free Float                  | 49.0%              |



Merrill Lynch does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

<sup>&</sup>gt;> Employed by a non-US affiliate of MLPF&S and is not registered/qualified as a research analyst under the NYSE/NASD rules.



# *iQprofile*<sup>™</sup> UltraTech Cement Ltd.

| Key Income Statement Data (Mar)                  | 2005A           | 2006A           | 2007E           | 2008E                  | 2009E             |
|--|-----------------|-----------------|-----------------|------------------------|-------------------|
| (Rs Millions)                                    |                 |                 |                 |                        |                   |
| Sales  | 26,811          | 32,995          | 46,942          | 53,227                 | 51,558            |
| Gross Profit                                     | 1,462           | 3,401           | 11,750          | 14,672                 | 10,782            |
| Sell General & Admin Expense                     | NA              | NA              | NA              | NA                     | NA                |
| Operating Profit                                 | 1,462           | 3,401           | 11,750          | 14,672                 | 10,782            |
| Net Interest & Other Income                      | (1,032)         | (896)           | (914)           | (914)                  | (1,866)           |
| Associates                                       | 0               | 0               | 0               | 0                      | (                 |
| Pretax Income                                    | 616             | 2,875           | 11,320          | 14,356                 | 9,592             |
| Tax (expense) / Benefit                          | (236)           | (858)           | (3,679)         | (4,594)                | (3,213)           |
| Net Income (Adjusted)                            | 380             | 2,016           | 7,641           | 9,762                  | 6,379             |
| Average Fully Diluted Shares Outstanding         | 124             | 124             | 124             | 124                    | 124               |
| Key Cash Flow Statement Data                     |                 |                 |                 |                        |                   |
| Net Income (Reported)                            | 380             | 2,016           | 7,641           | 9,762                  | 6,379             |
| Depreciation & Amortization                      | 2,034           | 2,142           | 2,187           | 2,641                  | 3,410             |
| Change in Working Capital                        | (1,103)         | (687)           | (1,600)         | (733)                  | 132               |
| Deferred Taxation Charge                         | NA              | NA              | NA              | NA                     | NA                |
| Other Adjustments, Net                           | (532)           | (48)            | 0               | (57)                   | (484)             |
| Cash Flow from Operations                        | 780             | 3,424           | 8,229           | 11,614                 | 9,436             |
| Capital Expenditure                              | (486)           | (2,600)         | (10,000)        | (14,990)               | (3,841)           |
| (Acquisition) / Disposal of Investments          | 533             | 0               | 0               | 0                      | (                 |
| Other Cash Inflow / (Outflow)                    | (352)           | 283             | 0               | 0                      | (2.2.41           |
| Cash Flow from Investing                         | (304)           | (2,318)         | (10,000)        | (14,990)               | (3,841)           |
| Shares Issue / (Repurchase)                      | (105)           | 0               | 0               | 0                      | (4.405            |
| Cost of Dividends Paid                           | (105)           | (454)           | (1,719)         | (2,197)                | (1,435            |
| Cash Flow from Financing                         | (332)           | 184             | 3,955           | 5,757                  | (4,008)<br>5,596  |
| Free Cash Flow<br>Net Debt                       | 295             | 824             | (1,771)         | (3,376)                |                   |
| Change in Net Debt                               | 14,751<br>(371) | 14,098<br>(653) | 17,489<br>3,490 | 23,156<br>5,572        | 19,032<br>(4,160) |
| •  | (3/1)           | (000)           | 3,470           | 5,572                  | (4,100            |
| Key Balance Sheet Data                           |                 |                 |                 |                        |                   |
| Property, Plant & Equipment                      | 25,971          | 26,429          | 34,241          | 46,589                 | 47,020            |
| Other Non-Current Assets                         | 1,848           | 1,848           | 1,848           | 1,848                  | 1,848             |
| Trade Receivables                                | 1,720           | 2,065           | 2,869           | 3,237                  | 3,17              |
| Cash & Equivalents                               | 563             | 1,854           | 4,137           | 6,424                  | 7,975             |
| Other Current Assets                             | 6,094           | 7,318           | 10,168          | 11,473                 | 11,238            |
| Total Assets                                     | 36,195          | 39,512          | 53,262          | 69,571                 | 71,251            |
| Long-Term Debt                                   | 12,870          | 13,508          | 19,182          | 27,136                 | 24,563            |
| Other Non-Current Liabilities<br>Short-Term Debt | 5,817<br>2,443  | 5,770<br>2,443  | 5,770<br>2,443  | 5,713<br>2,443         | 5,229<br>2,443    |
| Other Current Liabilities                        | 4,393           | 5,275           | 7,329           | 8,270                  | 8,10              |
| Total Liabilities                                | 25,524          | 26,996          | 34,725          | 43,563                 | 40,336            |
| Total Equity                                     | 10,671          | 12,516          | 18,438          | 26,004                 | 30,948            |
| Total Equity & Liabilities                       | 36,195          | 39,513          | 53,163          | 69,567                 | 71,28             |
| <i>iQmethod</i> <sup>sм</sup> - Bus Performance* | 30,173          | 37,313          | 33,103          | 07,307                 | 71,20             |
|  | 2.20/           | 0.00/           | 20.40/          | 10.40/                 | 12.20             |
| Return On Capital Employed Return On Equity      | 3.2%            | 8.0%<br>17.4%   | 20.6%<br>49.4%  | 19.4%                  | 12.2%             |
| Operating Margin                                 | 3.6%<br>5.5%    | 17.4%<br>10.3%  | 49.4%<br>25.0%  | 43.9%<br>27.6%         | 22.4%<br>20.9%    |
| EBITDA Margin                                    | 13.7%           | 17.9%           | 30.7%           | 33.7%                  | 28.8%             |
| iQmethod <sup>™</sup> - Quality of Earnings*     | 13.770          | 17.770          | 50.770          | 55.770                 | 20.07             |
| Cash Realization Ratio                           | 2.1x            | 1.7x            | 1 1 0           | 1.2x                   | 1 5               |
| Asset Replacement Ratio                          | 2.1x<br>0.2x    | 1.7x<br>1.2x    | 1.1x<br>4.6x    | 1.2x<br>5.7x           | 1.5               |
| Tax Rate (Reported)                              | 38.2%           | 29.9%           | 32.5%           | 32.0%                  | 1.1)<br>33.5%     |
| Net Debt-to-Equity Ratio                         | 138.2%          | 29.9%<br>112.6% | 94.9%           | 32.0 <i>%</i><br>89.0% | 61.5%             |
| Interest Cover                                   | 1.6x            | 4.2x            | 94.9%<br>13.4x  | 16.7x                  | 6.1               |
| Key Metrics                                      | 1.07            | 7.41            | 10.77           | 10.77                  | 0.17              |

<sup>\*</sup> For full definitions of *iQmethod* <sup>SM</sup> measures, see page 5.

#### **Company Description**

UltraTech is a 51% subsidiary of Grasim and was formed in 2004 via a demerger of L&T Cement, the cement division of the engineering company Larsen & Toubro. UltraTech is one of the largest cement companies in India with annual cement capacity of 17mn tons. It has 10 cement plants in all the regions of India, except the Northern region. It is also one of the largest exporters of cement and clinker.

#### Stock Data

Price to Book Value 7.7x

Table 1: 3Q FY07 results summary

| Yr to 31 Mar            | 3Q FY06A | 2Q FY07A | 3Q FY07A | YoY Chng | QoQ chng |
|-------------------------|----------|----------|----------|----------|----------|
| Total volumes (mn tons) | 3.8      | 3.7      | 4.5      | 18%      | 22%      |
| Rs mn                   |          |          |          |          |          |
| Net Turnover            | 7886     | 10045    | 12605    | 60%      | 25%      |
| Operating costs         | 6,783    | 7501     | 8802     | 30%      | 17%      |
| EBDIT                   | 1103     | 2545     | 3802     | 245%     | 49%      |
| EBDIT margin            | 14.0%    | 25.3%    | 30.2%    |          |          |
| Depreciation            | 515      | 547      | 571      | 11%      | 4%       |
| Operating profit        | 588      | 1998     | 3231     | 450%     | 62%      |
| Other income            | 71       | 119      | 167      | 135%     | 40%      |
| EBIT                    | 659      | 2117     | 3398     | 416%     | 61%      |
| Interest                | 228      | 237      | 202      | -11%     | -15%     |
| Profit before tax       | 431      | 1879     | 3196     | 642%     | 70%      |
| Tax                     | 192      | 605      | 1072     | 457%     | 77%      |
| Recurring net profit    | 239      | 1274     | 2125     | 790%     | 67%      |
| Net Margin              | 3.0%     | 12.7%    | 16.9%    |          |          |
| Non-recurring items     |          |          |          |          |          |
| Reported net profit     | 239      | 1274     | 2125     | 790%     | 67%      |

<sup>\*3</sup>Q FY06 numbers are not re-stated for Narmada Cement merger. Source: Company



# Price Objective Basis & Risk

Our price target of Rs1350/sh puts UltraTech at an EV/EBITDA of ~10-11x FY08E. This is based on a 20-25% discount versus valuations during the previous cyclical peak for cement in FY94-96. We think the discount captures risk of valuation compression as we move towards an expected cyclical reversal in FY09E.

Key risks to our positive outlook stem from 1) unforeseen cost pressures and 2) unexpected government intervention in cement pricing.

# **Analyst Certification**

I, Reena Verma Bhasin, CFA, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

# **Special Disclosures**

In accordance with the SEBI (Foreign Institutional Investors) Regulations and with guidelines issued by the Securities and Exchange Board of India (SEBI), foreign investors (individuals as well as institutional) that wish to transact the common stock of Indian companies must have applied to, and have been approved by SEBI and the Reserve Bank of India (RBI). Each investor who transacts common stock of Indian companies will be required to certify approval as a foreign institutional investor or as a sub-account of a foreign institutional investor by SEBI and RBI. Certain other entities are also entitled to transact common stock of Indian companies under the Indian laws relating to investment by foreigners. Merrill Lynch reserves the right to refuse copy of research on common stock of Indian companies to a person not resident in India. American Depositary Receipts (ADR) representing such common stock are not subject to these Indian law restrictions and may be transacted by investors in accordance with the applicable laws of the relevant jurisdiction. Global Depository Receipts (GDR) and the Global Depository Shares of Indian companies, Indian limited liability corporations, have not been registered under the U.S. Securities Act of 1933, as amended, and may only be transacted by persons in the United States who are Qualified Institutional Buyers (QIBs) within the meaning of Rule 144A under the Securities Act. Accordingly, no copy of any research report on Indian companies' GDRs will be made available to persons who are not QIBs.



#### iQmethod<sup>™</sup> Measures Definitions

Business Performance Numerator Denominator

Return On Capital Employed NOPAT = (EBIT + Interest Income) \* (1 - Tax Rate) + Goodwill Total Assets - Current Liabilities + ST Debt + Accumulated Goodwill

Amortization Amortization Shareholder

Return On Equity Net Income Shareholders' Equity
Operating Margin Operating Profit Sales

Earnings Growth Expected 5-Year CAGR From Latest Actual N/A
Free Cash Flow Cash Flow From Operations – Total Capex N/A

**Quality of Earnings** 

 Cash Realization Ratio
 Cash Flow From Operations
 Net Income

 Asset Replacement Ratio
 Capex
 Depreciation

 Tax Rate
 Tax Charge
 Pre-Tax Income

 Net Debt-To-Equity Ratio
 Net Debt = Total Debt, Less Cash & Equivalents
 Total Equity

Interest Cover EBIT

Valuation Toolkit

Price / Earnings RatioCurrent Share PriceDiluted Earnings Per Share (Basis As Specified)Price / Book ValueCurrent Share PriceShareholders' Equity / Current Basic Shares

Dividend Yield Annualised Declared Cash Dividend Current Share Price

Free Cash Flow Yield Cash Flow From Operations – Total Capex Market Cap. = Current Share Price \* Current Basic Shares

Enterprise Value / Sales EV = Current Share Price \* Current Shares + Minority Equity + Net Debt + Sales

EV / EBITDA Enterprise Value Basic EBIT + Depreciation + Amortization

iQmethod swis the set of Merrill Lynch standard measures that serve to maintain global consistency under three broad headings: Business Performance, Quality of Earnings, and validations. The key features of iQmethod are: A consistently structured, detailed, and transparent methodology. Guidelines to maximize the effectiveness of the comparative valuation process, and to identify some common pitfalls.

Interest Expense


iQdatabase® is our real-time global research database that is sourced directly from our equity analysts' earnings models and includes forecasted as well as historical data for income statements, balance sheets, and cash flow statements for companies covered by Merrill Lynch.

*iQprofile* <sup>SM</sup>, *iQmethod* <sup>SM</sup> are service marks of Merrill Lynch & Co., Inc.*iQdatabase* <sup>®</sup> is a registered service mark of Merrill Lynch & Co., Inc.

Other LT Liabilities

# **Important Disclosures**

### **XDJNF Price Chart**



B : Buy, N : Neutral, S : Sell, PO : Price objective, NA : No longer valid

The Investment Opinion System is contained at the end of the report under the heading "Fundamental Equity Opinion Key". Dark Grey shading indicates the security is restricted with the opinion suspended. Light Grey shading indicates the security is under review with the opinion withdrawn. Chart current as of December 31, 2006 or such later date as indicated.

#### Investment Rating Distribution: Building Group (as of 31 Dec 2006)

| investment rating bistribution. Di       | ullulling Oroup (as of s | 1 DCC 2000) |                             |       |         |
|--|--------------------------|-------------|-----------------------------|-------|---------|
| Coverage Universe                        | Count                    | Percent     | Inv. Banking Relationships* | Count | Percent |
| Buy                                      | 32                       | 47.76%      | Buy                         | 7     | 21.88%  |
| Neutral                                  | 31                       | 46.27%      | Neutral                     | 7     | 22.58%  |
| Sell                                     | 4                        | 5.97%       | Sell                        | 0     | 0.00%   |
| <b>Investment Rating Distribution: G</b> | lobal Group (as of 31 I  | Dec 2006)   |                             |       |         |
| Coverage Universe                        | Count                    | Percent     | Inv. Banking Relationships* | Count | Percent |
| Buy                                      | 1306                     | 42.74%      | Buy                         | 406   | 31.09%  |
| Neutral                                  | 1509                     | 49.38%      | Neutral                     | 446   | 29.56%  |
| Sell                                     | 241                      | 7.89%       | Sell                        | 53    | 21.99%  |

<sup>\*</sup> Companies in respect of which MLPF&S or an affiliate has received compensation for investment banking services within the past 12 months.

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium, and C - High. INVESTMENT RATINGS, indicators of expected total return (price appreciation plus yield) within the 12-month period from the date of the initial rating, are: 1 - Buy (10% or more for Low and Medium Volatility Risk Securities - 20% or more for High Volatility Risk securities); 2 - Neutral (0-10% for Low and Medium Volatility Risk securities - 0-20% for High Volatility Risk securities); 3 - Sell (negative return); and 6 - No Rating. INCOME RATINGS, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure); 8 - same/lower (dividend not considered to be secure); and 9 - pays no cash dividend.

In the US, retail sales and/or distribution of this report may be made only in states where these securities are exempt from registration or have been qualified for sale: UltraTech Cement.

The country in which this company is organized has certain laws or regulations that limit or restrict ownership of the company's shares by nationals of other countries: UltraTech Cement.

The analyst(s) responsible for covering the securities in this report receive compensation based upon, among other factors, the overall profitability of Merrill Lynch, including profits derived from investment banking revenues.



# Other Important Disclosures

UK readers: MLPF&S or an affiliate is a liquidity provider for the securities discussed in this report.

Information relating to Non-U.S. affiliates of Merrill Lynch, Pierce, Fenner & Smith Incorporated (MLPF&S):

Information relating to Non-U.S. affiliates of Merrill Lynch, Pierce, Fenner & Smith Incorporated (MLPF&S):

MLPF&S distributes research reports of the following non-US affiliates in the US (short name: legal name): Merrill Lynch (France): Merrill Lynch Capital Markets
(France) SAS; Merrill Lynch (Frankfurt): Merrill Lynch International Bank Ltd, Frankfurt Branch; Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd;
Merrill Lynch (Milan): Merrill Lynch International Bank Limited; MLPF&S (UK): Merrill Lynch, Pierce, Fenner & Smith Limited; Merrill Lynch (Australia): Merrill Lynch (Guite): Merrill Lynch (Singapore): Merrill Lynch (Ganada): Merrill Lynch (Canada): Merrill Lynch (Merrill Lynch (Merrill Lynch Mexico): Merrill Lynch (Seoul): Merrill Lynch (International Incorporated (Seoul Branch); Merrill Lynch (Taiwan): Merrill Lynch Global (Taiwan): Limited; DSP Merrill Lynch (India): DSP Merrill Lynch Limited; Merrill Lynch (Russia): Merrill Lynch CIS Limited, Mescow.

This research report has been prepared and issued by MLPF&S and/or one or more of its non-U.S. affiliates. MLPF&S is the distributor of this research report in the U.S. and accepts full responsibility for research reports of its non-U.S. affiliates distributed in the U.S. Any U.S. person receiving this research report and wishing

the O.S. and accepts unlesponsibility of research reports on its hori-ous. Allighted in the O.S. and accepts unlesponsibility of research report and wishing to effect any transaction in any security discussed in the report should do so through MLPF&S and not such foreign affiliates.

This research report has been approved for publication in the United Kingdom by Merrill Lynch, Pierce, Fenner & Smith Limited, which is authorized and regulated by the Financial Services Authority; has been considered and distributed in Japan by Merrill Lynch Japan Securities Co, Ltd, a registered securities dealer under the Securities and Exchange Law in Japan; is distributed in Hong Kong by Merrill Lynch (Asia Pacific) Limited, which is regulated by the Hong Kong SFC; is issued and distributed in Taiwan by Merrill Lynch Global (Taiwan) Ltd or Merrill Lynch, Pierce, Fenner & Smith Limited (Taiwan Branch); is issued and distributed in Malaysia by Merrill Lynch (KL) Sdn. Bhd., a licensed investment adviser regulated by the Malaysian Securities Commission; and is issued and distributed in Singapore by Merrill Lynch International Bank Limited (Merchant Bank) and Merrill Lynch (Singapore) Pte Ltd (Company Registration No.'s F 06872E and 198602883D respectively). Merrill Lynch International Bank Limited (Merchant Bank) and Merrill Lynch (Singapore) Pte Ltd. are regulated by the Monetary Authority of Singapore. Merrill Lynch Equities (Australia) Limited, (ABN 65 006 276 795), AFS License 235132, provides this report in Australia. No approval is required for publication or distribution of this report in Brazil.

Merrill Lynch (Frankfurt) is regulated by BaFin.

Copyright, User Agreement and other general information related to this report:

Copyright 2007 Merrill Lynch, Pierce, Fenner & Smith Incorporated. All rights reserved. This research report is prepared for the use of Merrill Lynch clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Merrill Lynch. Merrill Lynch research reports are distributed simultaneously to internal and client websites eligible to receive such research prior to any public dissemination by Merrill Lynch of the research report or information or opinion contained therein. Any unauthorized use or disclosure is prohibited. Receipt and review of this research report constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets) prior to Merrill Lynch's public disclosure of such information. The information herein (other than disclosure information relating to Merrill Lynch and its affiliates) was obtained from various sources and we do not guarantee its accuracy. Merrill Lynch makes no representations or warranties whatsoever as to the data and information provided in any third party referenced website and shall have no liability or responsibility arising out of or in connection with any such referenced website.

This research report provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment or any options, futures or derivatives related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that price or value of such securities and investments may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or related investment mentioned in this report. In addition, investors in securities such as ADRs, whose values are influenced by the currency of the underlying security, effectively assume currency risk.

Officers of MLPF&S or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related

Merrill Lynch Research policies relating to conflicts of interest are described at http://www.ml.com/media/43347.pdf.

iQmethod, iQmethod 2.0, iQprofile, iQtoolkit, iQworks are service marks of Merrill Lynch & Co., Inc. iQanalytics®, iQcustom®, iQdatabase® are registered service marks of Merrill Lynch & Co., Inc.

Fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.